• The "Global Atosiban Acetate Injection Market" was valued at US$ 292.8 million in 2024 and is projected to reach US$ 480.3 million by 2030, at a CAGR of 8.6% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
• The global key manufacturers of Atosiban Acetate Injection include Bachem, Piramal Pharma Solutions, Transo-Pharm, Rochem International, Suanfarma, Teva Pharmaceutical Industries, PolyPeptide Group, Emcure Pharmaceuticals and Smaart Pharmaceutticals, etc. in 2024, the global top five players have a share approximately % in terms of revenue.
• Atosiban Acetate Injection is a tocolytic that can be used in IVF to protect the pregnancy, and the principle of action is to prevent the increase of calcium ions in the cells, relax the smooth muscle of the uterus, reduce uterine contractions and help embryo implantation.
• This report aims to provide a comprehensive presentation of the global market for Atosiban Acetate Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Atosiban Acetate Injection. This report contains market size and forecasts of Atosiban Acetate Injection in global, including the following market information:
Email: help@24marketresearch.com
Call: 1(332) 2424 294 (Int'l)
